Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-DOTA-hTAB004
- Development stage
- Preclinical
- Lead developer
- OncoTTab
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
111In-DOTA-hTAB004 is a radiolabeled humanized monoclonal antibody being developed by OncoTab for the diagnostic imaging of tumors expressing transformed MUC1 (tMUC1). The agent consists of the hTAB004 antibody conjugated to a DOTA chelator and radiolabeled with Indium-111, enabling tumor localization via Single-Photon Emission Computed Tomography (SPECT). tMUC1 is a cancer-specific glycoform of MUC1 that is highly overexpressed in triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma, but absent in normal tissues. This agent is being developed as a companion diagnostic for tMUC1-targeted therapies, particularly the alpha-particle therapeutic 225Ac-DOTA-hTAB004, forming a theranostic pair for precision oncology. Preclinical studies have demonstrated high tumor accumulation and favorable biodistribution in orthotopic TNBC models.
- Other names
- Indium-111 DOTA-hTAB004Indium111 DOTA-hTAB004Indium 111 DOTA-hTAB004111In-hTAB004radiolabeled hTAB004
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on 111In-DOTA-hTAB004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111In-DOTA-hTAB004.